ClinicalTrials.gg
CompletedNCT00800735Updated Oct 30, 2013Results posted

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

A Phase 3 interventional study of Pegylated-interferon alfa-2a and Ribavirin in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 23 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-30.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.

Enrollment
71st of 83
30 · median 129
Started
2009
with 3 others
Phase 3
19 of 83
none open now
Registered
47th of 83
by date
Lead sponsor
35 of 83
Hoffmann-La Roche

Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 71st largest by enrollment, is one of 4 that started in 2009, is one of 19 in phase 3, and was the 47th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic as a file.
02

Study summary

This single arm study will provide treatment or re-treatment with PEGASYS as monotherapy or in combination with ribavirin (Copegus), to patients with chronic hepatitis C (CHC) who have participated in a previous Roche or Roche partner protocol where access to treatment or re-treatment was promised or deemed appropriate following completion of the original protocol ('donor' protocol). Patients who qualify for treatment or re-treatment will begin PEGASYS monotherapy, at a maximum dose of 180 µg weekly, or combination therapy with Copegus, 800-1200 mg daily, as continuation of treatment after the wash-out period defined in their donor protocol. PEGASYS treatment is not to exceed the approved treatment duration of 48 weeks in genotype G1 with a treatment-free follow up period of 24 weeks.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, ≥ 18 years of age.
  • Chronic (CHC) patients with compensated liver disease ( A) who have participated in a donor protocol where access to treatment or re-treatment with PEGASYS monotherapy or in combination with Copegus was promised or deemed appropriate after completion of the donor protocol.

Exclusion criteria

Exclusion Criteria:

  • Evidence of decompensated liver disease (Child B or C cirrhosis).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Pegylated-interferon alfa-2a plus ribavirin

    Participants received pegylated-interferon alfa-2a 180 µg/week subcutaneously plus ribavirin 1000 mg/day orally for patients weighing \< 75 kg or 1200 mg/day for patients weighing ≥ 75 kg for 48 weeks.

    Drug: Pegylated-interferon alfa-2a · Drug: Ribavirin

Interventions

  • Pegylated-interferon alfa-2a was administered subcutaneously once weekly.

    Also known as: PEG-IFN alfa-2a, Pegasys

  • Participants received ribavirin with food, as the bioavailability of ribavirin is increased when taken with food. Ribavirin was administered as split doses, that is, 2 doses were given 12 hours apart, 1 in the morning and 1 in the evening. Participants received either 1000 or 1200 mg ribavirin per day according to body weight: 400 mg (2 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing \< 75 kg or 600 mg (3 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing ≥ 75 kg.

    Also known as: Copegus, Ro 20-9963

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced at Least 1 Adverse Event.

    An adverse event is any untoward medical occurrence in a patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: Baseline through 24 weeks after the end of treatment (up to 72 weeks)

07

Results

Posted Sep 13, 2013

Participant flow

Participant flow — Overall Study
MilestonePegylated-interferon Alfa-2a Plus Ribavirin
Started30
Completed16
Not completed14
Withdrew: Administrative/other2
Withdrew: Insufficient therapeutic response2
Withdrew: Violation of selection criteria at entry7
Withdrew: Withdrew consent3

Outcome measures

PrimaryPercentage of Participants Who Experienced at Least 1 Adverse Event.

An adverse event is any untoward medical occurrence in a patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
Baseline through 24 weeks after the end of treatment (up to 72 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced at Least 1 Adverse Event.
Percentage of participantsPegylated-interferon Alfa-2a Plus Ribavirin
Percentage of Participants Who Experienced at Least 1 Adverse Event.80.0

Adverse events

Collected over Adverse events from the beginning of treatment up to 24 weeks after the end of treatment were reported.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegylated-interferon Alfa-2a Plus Ribavirin—4/30 (13.3%)23/30 (76.7%)
Most frequent serious events
Most frequent serious events
EventPegylated-interferon Alfa-2a Plus Ribavirin
Retinal haemorrhageEye disorders1/30
Conjunctivitis viralInfections and infestations1/30
LaryngitisInfections and infestations1/30
SinusitisInfections and infestations1/30
Arthropod biteInjury, poisoning and procedural complications1/30
Rib fractureInjury, poisoning and procedural complications1/30
Prothrombin time prolongedInvestigations1/30
HaemoptysisRespiratory, thoracic and mediastinal disorders1/30
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPegylated-interferon Alfa-2a Plus Ribavirin
FatigueGeneral disorders16/30
PruritusSkin and subcutaneous tissue disorders9/30
NauseaGastrointestinal disorders8/30
ChillsGeneral disorders7/30
HeadacheNervous system disorders7/30
InsomniaPsychiatric disorders7/30
RashSkin and subcutaneous tissue disorders6/30
AstheniaGeneral disorders5/30
Influenza like illnessGeneral disorders5/30
DepressionPsychiatric disorders5/30

Baseline characteristics

Age Continuous
Age Continuous(years)Pegylated-interferon Alfa-2a Plus Ribavirin
Mean48.5 ± 9.35
Sex: Female, Male
Sex: Female, Male(Participants)Pegylated-interferon Alfa-2a Plus Ribavirin
Female18
Male12
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pegylated-interferon Alfa-2a Plus Ribavirin
Black2
Caucasian28
Height
Height(cm)Pegylated-interferon Alfa-2a Plus Ribavirin
Mean170.0 ± 7.28
Weight
Weight(kg)Pegylated-interferon Alfa-2a Plus Ribavirin
Mean76.97 ± 16.146
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Pegylated-interferon Alfa-2a Plus Ribavirin
Mean26.5 ± 4.53
08

Study locations

23 sites
  • Sacramento, California 95817, United States
  • San Francisco, California 94115, United States
  • Lutherville, Maryland 21093, United States
  • Manhasset, New York 11030, United States
  • New York, New York 10021, United States
  • Chapel Hill, North Carolina 27599-7584, United States
  • Portland, Oregon 97239, United States
  • Providence, Rhode Island 02905, United States
  • Nashville, Tennessee 37203, United States
  • San Antonio, Texas 78215, United States
  • Salt Lake City, Utah 84132, United States
  • Wien, 1090, Austria
  • Vancouver, British Columbia V5Z 1H2, Canada
  • Vancouver, British Columbia V5Z 1M9, Canada
  • Toronto, Ontario M5G 1L7, Canada
  • Clichy, 92118, France
  • Berlin, 10969, Germany
  • Frankfurt Am Main, 60590, Germany
  • Koeln, 50924, Germany
  • Badalona, 08915, Spain
  • Barcelona, 08003, Spain
  • Madrid, 28222, Spain
  • Valencia, 46014, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2008
First posted
Dec 2, 2008
Start
Apr 2009
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Results first posted
Sep 13, 2013
Last update
Oct 30, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00800735
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 2, 2008
Start date
Apr 2009
Primary completion
Mar 2012
Completion
Mar 2012
Results posted
Sep 13, 2013
Last update
Oct 30, 2013

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin

Start the discussion